Companies Forge Ahead With New Devices, Studies, And Funding For Treatment-Resistant Hypertension
Executive Summary
With Medtronic planning to submit an IDE application to the FDA soon to conduct a new US trial of its renal denervation technology, companies and investors alike remain optimistic about finding an effective device-based therapy for treatment-resistant hypertension. Two smaller players in this space – Rox Medical and Verve Medical – are also forging ahead, due to recently published encouraging study results for Rox’s stent-like implant, Coupler, and a nearly $2 million Series B1 round to fund further clinical trials of Verve’s Phoenix RF energy device.
You may also be interested in...
Renal Denervation: Stepping Back To Move Forward
With the announcement that Medtronic is going back to the clinical drawing board after the pivotal SYMPLICITY HTN-3 trial of its renal denervation device failed to meet its primary efficacy endpoint, the industry is taking a cautious but still optimistic stance on the highly touted potential treatment for resistant hypertension.
Almost All Top German OTC Companies Have Now Raised Prices Due To Inflation – Sempora
87 of the top 100 German OTC manufacturers are now reporting inflation-driven price increases, up from 72 at the same point last year. Sempora Consulting suggests a number of strategies to address the current economic challenges companies face.
Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR
When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.